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Background: As EBV-associated gastric cancer has unique features that are different from EBV (-) gastric cancer,
EBV is considered to have a key role in gastric carcinogenesis. It has been reported that viral latent membrane
protein 2A (LMP2A) in EBV-transformed tumor cells activates the phosphatidylinositol 3-kinase (PI3K)/AKT pathway,
which provides a survival signal and chemo-resistance to cytotoxic anti-cancer drugs. This study was to evaluate
anti-proliferative effect and cell cycle change when 5-FU and LY294002 (LY), a selective inhibitor of PI3K, were
treated separately or combined with different schedules in EBV positive gastric cancer cell line, SNU-719.
Methods: After single treatment and sequential combination of 5-FU and LY, cytotoxic activity was measured by
MTS assay. When 5-FU and LY were treated in single and sequential combinations, the expression of p-AKT, p-
NFkB, p-p53 and bcl-2 was observed on different concentrations by Western blot analysis. We also investigated the
effect on apoptosis and cell cycle distribution using flow cytometry. The LMP2A siRNA inhibition was done to
confirm the reversal of decreased 5-FU activity and p-AKT.
Results: When 5-FU was sequentially combined with LY, the combination index (CI) value indicated synergistic
anti-proliferative effect. The expression of p-AKT and p-NFB was upregulated by 5-FU alone but sequential
treatment of 5-FU and LY decreased the expression of both p-AKT and p-NFB. When 5-FU was combined with LY,
G0/G1 and sub G1 cell population (%) increased. When 5-FU was added to the cells transfected with LMP2A siRNA,
its anti-proliferative effect increased and the expression of p-AKT decreased. In sequential combination of 5-FU and
LY, the expression of p-p53 was increased and bcl-2 expression was diminished compared to 5-FU alone.
Conclusion: These data suggest that sequential combination of 5-FU and LY induce synergistic cytotoxicity and
overcome intrinsic and acquired resistance of 5-FU via downregulation of activated p-AKT and mitochondria-
dependent apoptosis in EBV gastric cancer cell line, SNU-719.
Background
The worldwide incidence of gastric adenocarcinoma is
estimated to exceed 75,000 cases/year, and recent stu-
dies have shown that Epstein-Barr virus (EBV) is asso-
ciated with 10%-18% of gastric cancers. In Korea,
EBV-positive cells are found in 7%-10% of gastric can-
cers and the occurrence of EBV-positive gastric cancers
is estimated to be around 4,500-6,400 cases/year based
on the fact that gastric cancer has the highest incidence
of all cancers.
EBV not only causes infectious mononucleosis, but is
also a herpes virus with oncogenic potential, giving rise
to Burkitt’s lymphoma, nasopharyngeal carcinoma,
Hodgkin’s disease, B-cell lymphoma in immunodeficient
patients, and gastric carcinoma [1].
Of the six types of identified EBV nuclear antigens
(EBNAs), only EBNA1 is expressed in gastric carcinoma,
and of the three latent membrane proteins (LMPs),
LMP1 and LMP2B are not expressed, although LMP2A
is expressed in some cases. The BARF0 gene in the
BamHI-A region and the EBER genes (EBER1 and
EBER2) are always expressed. The transcription of these
genes is tightly regulated to maintain the virus in a dor-
mant state in host cells [2].
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include the prevention of viral oncogene expression,
eliminator of the EBV episome, and induction of the
EBV infection to the lytic cycle. Ganciclovir (GCV) is an
antiviral drug that can be used to treat cancers if the
virus in the tumor cells becomes lytic. Host cells with
the lytic type of EBV infection, but not the latent type,
express virally encoded kinases that can phosphorylate
the prodrug, GCV, and convert it to its active cytotoxic
form. Furthermore, phosphorylated GCV can be trans-
ferred to nearby cancer cells, thus inducing ‘by-stander
killing.’ Because EBV-positive gastric tumor cells are pri-
marily infected with the latent form of EBV, GCV itself
is not effective in treating EBV-positive gastric cancers
until the virus enters its replicative lytic cycle [3,4].
A recent study confirmed that chemotherapeutic
agents (5-fluorouracil [5-FU], cisplatin, and paclitaxel)
induce the expression of the immediate early proteins
BMRF1, BZLF1, and BRLF1 [4]. Both BZLF1 and BRLF1
are transcription factors that activate the transcription
of other genes involved in the lytic conversion of the
virus. Three different signal transduction pathways (the
p38 stress mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K), and protein kinase
C δ pathways) are known to be important in the induc-
tion of lytic EBV infections by cytotoxic chemotherapeu-
tic agents.
The main cause of treatment failure in advanced gas-
tric cancer is the development of chemoresistance to
cytotoxic chemotherapies. The chemoresistance to che-
motherapeutic drugs probably involves an anti-apoptosis
effect. Therefore, a novel therapeutic strategy is required
to target cellular signaling molecules in the presence of
the virus in malignant cells.
LMP2A is expressed as a transmembrane protein in
latently infected cells at latency stages I, II, and III. This
viral protein drives the proliferation and survival of B
cells in the absence of signaling through the B-cell
receptor and simultaneously activates the PI3K/AKT
pathway, which is involved in the survival of latently
infected B cells [5]. It has transforming capacity, alters
epithelial cell motility, and inhibits epithelial cell differ-
entiation. LMP2A expression influences the expression
of a range of genes involved in cell-cycle induction, the
inhibition of apoptosis, and the suppression of cell-
mediated immunity [6]. In addition to viral proteins,
changes in cellular signaling molecules caused by EBV
contribute to resistance to the cytotoxic anti-cancer
drugs (5-FU, cisplatin, and paclitaxel) used for gastric
cancer. A number of cellular mechanisms that contri-
bute to chemoresistance have been described. These
include upregulation of the multidrug-resistance gene
product and mutation of the p53 tumor suppressor
gene, which impairs the p53-dependent induction of
apoptosis [7,8]. EBV-positive gastric carcinomas tend to
express much higher amounts of p53 than do EBV-
negative carcinomas [2,9]. Leung et al [10] reported that
EBV-positive gastric carcinomas show weak to moderate
p53 expression at various stages of the disease, indicat-
ing a role for EBV in a non-mutational mechanism
of p53 overexpression. High Bcl-2 expression in EBV-
positive gastric carcinoma might protect tumor cells
from apoptosis [11].
Previous in vitro studies have reported that several
chemotherapeutic agents, including 5-FU, paclitaxel, vin-
blastine, vincristine, daunomycin, and doxorubicin, can
activate nuclear factor B( N F - B), and that this
response results in marked suppression of the cell’s
apoptotic potential [12,13].
AKT, a serine/threonine kinase, is a key molecule in
protecting cells from apoptosis, and the AKT-mediated
survival signaling pathway is an attractive target for can-
cer chemotherapy. The activation of AKT inactivates the
expression of caspase 9 and regulates the expression of
the apoptosis-inducing FAS ligand [14,15]. It also phos-
phorylates IB, promoting IB degradation, thereby
increasing the activity of the well-known cell survival
factor, NFB. The expression of AKT is altered in var-
ious human tumors, and this aberrant expression may
contribute to chemoresistance [16-18]. AKT-mediated
chemoresistance is likely to result from overall anti-
apoptotic activity of AKT and activation of the PI3K
signaling cascade, which leads to multidrug resistance.
It has been reported that cytotoxic chemotherapeutic
agents, including 5-FU, doxorubicin, and cisplatin, can
induce lytic EBV gene transcription in latently infected
EBV-positive cell lines, and that the EBV viral protein
LMP2A activates the PI3K/AKT pathway, which leads
to maintenance of the latent form [19]. We examined
whether treatment with 5-FU or LY294002 alone or in
combination induces the activation of phosphorylated
AKT (p-AKT). We also investigated whether the inhibi-
tion of p-AKT enhances the growth inhibitory and
apoptotic effects of chemotherapeutic agents in gastric
cancer cells. The object of this study was to evaluate the
role of p-AKT in inducible chemoresistance and to
overcome this resistance by 5-FU/LY2940002 combina-
tion treatment.
Methods
1) Cell culture and reagents
The EBV-negative AGS gastric cancer cell line and the
EBV-positive SNU-719 gastric cancer cell line were
obtained from the Korea Cell Line Bank (Seoul, Korea).
They were maintained in Roswell Park Memorial Insti-
tute (RPMI) 1640 culture medium supplemented with
streptomycin (100 g/mL) and penicillin (100 U/mL),
glutamine (2 mM), and 10% (v/v) fetal bovine serum
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humidified atmosphere containing 5% CO2. LY294002
and 5-FU were purchased from Sigma (St Louis, MO).
They were dissolved in dimethyl sulfoxide (DMSO)
before use in the cytotoxicity assay. The final concentra-
tions of the DMSO were 0.1% or less in drugs. Metha-
nethiosulfonate (MTS) was purchased from Promega
(San Luis Obispo, CA).
2) Treatment schedules
The cell lines exhibited a wide range of sensitivity to 5-
FU and LY294002 in single and sequential treatments.
Combination studies involved treatment with an initial
24 h or 48 h exposure to 10 μM 5-FU, followed by addi-
tional 24 h or 48 h treatment with 20 μM LY294002.
3) Cytotoxicity
AGS and SNU-719 cells were seeded in 96-well plates at
pre-determined cell densities (2 × 10
3 cell/100 μL/well
and 7 × 10
3 cell/100 μL/well, respectively). After over-
night incubation to allow the cells to attach to the bot-
toms of the wells, the cells were treated singly with 5-
FU (0.1-300 μM) or LY294002 (0.1-80 μM) diluted in
D M S Of o r2 4h ,4 8h ,o r7 2h ,o rw i t has e q u e n t i a l
application of the drugs.
Cell viability was evaluated with an MTS assay 72 h
after exposure to the drugs. The sensitivity of tumor
cells to 5-FU (5-FU treatment alone or in combination
with LY294002) was determined by estimating the IC50
values (doses that induce 50% growth inhibition) for
5-FU from the dose-response curves. Interactions
between 5-FU and LY294002 were expressed as the
combination index (CI) on a CI-isobologram (Kanazawa
et al., 1997): ≤ 0.8 represents synergistic cytotoxicity; 0.8
< CI <1 represents additive cytotoxicity; and ≥ 1r e p r e -
sents antagonistic cytotoxicity.
4) Western blotting
AGS and SNU-719 cells were cultured in 100 mm
dishes and treated with 5-FU or LY294002 using the
protocols described above. The cells were lysed with
lysis buffer (0.02 M Tris, 0.15 M NaCl, 0.1% sodium
dodecyl sulfate [SDS], 1% Triton X-100, 1% sodium
deoxycholate [pH 7.5 with HCl], 0.02 mM phenyl-
methylsulfonyl fluoride, 0.1 mM NaF, 0.01 mg/mL leu-
peptin, 0.01 mg/mL pepstatin) and then centrifuged at
12,000 × g for 30 min at 4°C. The amount of protein
was determined with the Bradford protein assay (Bio-
Rad). The lysates (40 μg/lane) were boiled for 5 min,
separated by 10%-12% SDS-polyacrylamide gel electro-
phoresis, and transferred to polyvinylidene difluoride
membrane (Amersham Biosciences, Piscataway, NJ). The
membranes were incubated for 1 h with blocking buffer
(5% nonfat milk and 0.1% Tween 20 in Tris-buffered
saline [TBS-T]) and overnight with mouse monoclonal
antibodies directed against basic fibroblast growth factor
(1:1000 dilution; Santa Cruz Biotechnology Inc., Santa
Cruz, CA), p-NFB (1:200 dilution; Cell Signaling),
p-AKT (1:500 dilution; Santa Cruz Biotechnology Inc.),
or total AKT (1:500 dilution; Cell Signaling), or rabbit
monoclonal antibodies directed against p-p53, Bcl-2, or
Bak1 (1:2,000; Santa Cruz Biotechnology Inc.), or mouse
polyclonal antibody directed against BAX (1:2,000; Santa
Cruz Biotechnology Inc.). The membranes were washed
three times with TBS-T and incubated for 1 h with
horseradish-peroxidase-conjugated donkey anti-mouse
IgG or donkey anti-rabbit IgG antibody (Santa Cruz
Biotechnology Inc.). The proteins were detected with
enhanced chemiluminescence reagent (ECL kit, Amer-
sham Biosciences).
5) Cell-cycle analysis
Cells were seeded in 150 mm dishes (5-7 × 10
5 cells/
dish) and treated with 5-FU (10 μM) or LY294002 (20
μM) alone or sequentially in combination for 24 h, 48 h,
or 72 h. The cells were harvested and fixed overnight
with cold 70% ethanol at -20°C. The fixed cells were
washed with phosphate-buffered saline, stained with
0.05 mg/mL propidium iodide, and treated with 1 mg/
mL RNase A in a water bath (37°C) for 15 min. Ana-
lyses of 10,000 events were acquired on a FACS Calibur
flow cytometer (Becton Dickinson Biosciences), and the
cell cycles were analyzed using the ModFit DNA analy-
sis software (Verity Software House).
6) Apoptosis
Apoptosis was measured by flow cytometry after con-
current staining with fluorescein-conjugated annexin V
and propidium iodide (Annexin V-FITC kit, Becton
Dickinson). In brief, AGS and SNU-719 cells were trea-
ted with 5-FU for 48 h, then with LY294002 for 24 h,
and the cells were collected, washed, and stained with
annexin V-propidium iodide before being subjected to
flow-cytometric analysis.
In another experiment, the nuclear chromatin of the
cells was stained with the fluorogenic compound 4′,
6-diamidino-2-phenylindole (DAPI) to assess any mor-
phological changes. SNU-719 cells (about 1 × 10
5 cells)
were treated with 5-FU or LY294002 singly or in combi-
nation, as described previously, then fixed in 10% for-
maldehyde before the cells were attached to glass
microscope slides by Cytospin at 700 rpm for 5 min.
The slides were then stained with DAPI solution (1:500,
Pierce) for 10 min. The cells were visualized under a
fluorescence microscope with a blue filter (330-380 nm)
to identify any morphological features of apoptosis, such
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formation of apoptotic bodies (AX70, Olympus). All the
experiments were performed in triplicate.
7) RNA interference
RNA duplexes were synthesized by Samchullypharm
(Korea). The siRNA target sequence for LMP2A mRNA
was 5′-AACUCCCAAUAUCCAUCUGCU-3′.T h e
LMP2A siRNA was designed such that it did not over-
lap sequences shared by LMP2B. A control scrambled
siRNA duplex was also produced by Samchullypharm
(Scramble II Duplex). The siRNA duplex was transfected
using Lipofectamine2000 Reagent (Invitrogen) as recom-
mended by the manufacturer and the cells were assayed
for silencing 2 days after transfection. All experiments
were performed in triplicate, and at least two indepen-
dent experiments were performed for each of the cell
lines.
8) Statistical analysis
All data are expressed as the mean ± standard deviation
(SD) of at least three independent experiments. Two-
tailed, paired Student’s t test and one-way ANOVA
were used to determine the differences between the con-
trol and treatment groups (Analyze-It software for
Microsoft Excel).
Results
1) Enhanced cytotoxic effect of 5-FU with the PI3K
inhibitor LY294002
5-FU or LY294002 was applied to SNU-719 and AGS
cells at different drug concentrations (0.1-300 μM) for
72 h. The cytotoxicity of 5-FU was measured in EBV-
negative AGS cells and EBV-positive SNU-719 cells,
which produced IC50 values of 11.6 ± 9.2 μMa n d2 2 . 9
± 2.8 μM( P < 0.01), respectively. IC50 for 5-FU in SNU-
719 cells was two-fold higher than that in AGS cells,
with approximately 30% of cells remaining alive at con-
centrations of more than 300 μM( F i g u r e1 A ) .I nc o n -
trast, the IC50 values for LY294002 in SNU-719 and
AGS cells were not significantly different, being 5.1 ±
2.4 μM and 8.9 ± 0.6 μM( P > 0.05), respectably (Figure
1B). We hypothesized that if the induction of the PI3K/
AKT pathway by LMP2A contributes to 5-FU resistance
in EBV-positive gastric cancer cells, the combination of
5-FU with specific inhibitors of the PI3K pathway may
result in a synergistic effect in EBV-positive gastric can-
cer cell lines, such as SNU-719 cells. Combined treat-
ments with various concentrations of 5-FU and
LY294002 resulted in the reduced growth of SNU-719
cells compared with that observed with 5-FU treat-
ments. The CI values for 5-FU and LY294002 were cal-
culated from the results of the experiments presented in
Figure 2. When the isobologram was analyzed, the CI
values were 0.36 and 1.1 in EBV-positive (SNU-719
cells) and EBV-negative (AGS cells) gastric cancer cells,
respectively. This indicates that 5-FU and LY294002
used in combination act with synergistic effect in SNU-
719 cells and additive effect in AGS cells (Figure 2).
2) The combination of 5-FU and LY294002 influences the
expression of downstream signal molecules
To verify that the antiproliferative effect of 5-FU com-
bined with LY294002 is attributable to the inhibition of
the PI3K and/or NFB signal pathways, we investigated
the activation status of their downstream components
by Western blot analysis.
5-FU induced the expression of p-AKT in a dose-
dependent manner in both SNU-719 and AGS cells.
Figure 1 Dose-response curves for single 5-FU and LY294002
treatments of AGS and SNU-719 gastric cancer cell lines. Dose-
dependent inhibition of cell proliferation by 5-FU and LY294002 in
gastric cancer cells. Cells were treated with increasing
concentrations of 5-FU (A) or LY294002 (B) for 72 h, and the viable
cells were quantified by MTS assay. The data presented are the
mean ± SD of three independent experiments.
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phorylated NFB( p - N F B) in SNU-719 cells, but
reduced it in AGS cells. In contrast, LY294002 reduced
p-AKT expression but increased p-NFB expression in a
dose-dependent manner (Figure 3A). In AGS cells, two
sequential treatments with 5-FU (at 24 h and 48 h) fol-
lowed by LY294002 (at 48 h and 24 h) reduced p-AKT
and increased p-NFBe x p r e s s i o nt oag r e a t e rd e g r e e
than did 5-FU alone (24 h). The changes in p-AKT and
p-NFB expression in SNU-719 cells were similar to
t h o s ei nA G Sc e l l sw h e n5 - F Uw a sc o m b i n e dw i t h
LY294002 in a sequential manner (5-FU at 24 h ®
LY294002 at 48 h). However, sequential treatment with
5-FU (48 h) followed by LY294002 (24 h) markedly
reduced the expression of both p-AKT and p-NFB
compared with that in cells treated with 5-FU alone for
24 h or 48 h (Figure 3B).
In SNU-719 EBV-positive gastric cancer cells, the
basal expression of p-AKT may be enhanced through
the LMP2A-mediated amplification of the PI3K/AKT
pathway, conferring resistancy to 5-FU treatment.
Thereby, we examined if chemoresistance to 5-FU was
caused by the induction of p-AKT expression as well as
p-NFBe x p r e s s i o n .O u rd a t as uggest that the reduced
expression of p-AKT and p-NFB following LY294002
treatment overcomes 5-FU resistance in EBV-positive
gastric cancer cells.
3) Combination of 5-FU and LY294002 affects the cell
cycle and its regulators
The cell-cycle distribution was analyzed in SNU-719
cells exposed to 5-FU or LY294002 singly or in combi-
nation for 72 h by flow cytometry and Western blotting.
5-FU (48 h) induced S-phase arrest in 32.5 ± 1.5% of
Figure 2 Isobolograms showing the interaction between 5-FU
and LY294002 in AGS and SNU-719 cells. Synergistic analysis of
the interaction between 5-FU and LY294002 in AGS and SNU-719
gastric cancer cells. The interaction between 5-FU and LY294002
given on the schedule 5-FU ® LY294002 is shown with an
isobologram technique. The experimental isoeffect points are the
concentrations (expressed relative to the 5-FU and LY294002 IC50
concentrations) of the two agents which, when combined, reduced
cell viability by 50%. The data points above the diagonal line of the
additive effects in the isobole suggest antagonism; those below the
diagonal line suggest synergism. The isobologram analysis was
based only on data obtained directly from actual experiments.
Figure 3 Expression of phosphorylated AKT and
phosphorylated NFB in AGS and SNU-719 gastric cancer cells
measured by Western blot analysis. (A) Dose-dependent
expression of p-AKT and p-NFB in AGS and SNU-719 gastric cancer
cells. (B) Schedule-dependent expression of p-AKT and p-NFBi n
AGS and SNU-719 gastric cancer cells. The data are the mean ± SD
of three independent experiments.
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G0/G1 phase arrest in 54.8 ± 3.5% of cells. Treatment
with 5-FU (48 h) followed by treatment with LY294002
(24 h) induced G0/G1 phase arrest in 49.3 ± 7.5% of
cells, S phase in 10.8 ± 5.9% of cells, and G2/M phase in
39.9 ± 4.3% of cells (Figure 4A).
The expression of phase-specific cyclins and cyclin-
dependent kinases (CDKs), as determined by immuno-
blotting in parallel experiments, was compatible with
the cell-cycle distribution (Figure 4B). 5-FU increased
the expression of cyclin A (Figure 4B, lane 3) compared
with that in untreated cells (Figure 4B, lane 1), which is
consistent with S-phase arrest. LY294002 inhibited the
expression of cyclin D3 and slightly increased the
expression of CDK2, CDK4, and cyclin A (Figure 4B,
lane 2) compared with that in untreated cells (Figure
4B, lane 1), consistent with G1-phase arrest. Compared
with 5-FU treatment (48 h), combined treatment with
5-FU and LY294002 downregulated the expression of
cyclin D3 and CDK2, and upregulated the expression of
cyclin A and CDK4 (Figure 4B, lane 4).
4) Sequential combination of 5-FU with LY294002 leads
to increased apoptotic cell death
To investigate whether the sequential combination of
drugs induces apoptotic cell death more effectively than
does the individual treatments, we looked for morpholo-
gical changes and quantitatively measured the apoptotic
cell population in SNU-719 cells treated with 5-FU,
LY2940002, or their sequential combination. The cells
treated with the sequential combination (5-FU followed
by LY294002) showed nuclear fragmentation with DAPI
staining (Figure 5A). We observed DNA condensation
and large nuclei in the cells treated with 5-FU (48 h)
follow by LY294002 (24 h). Sequential treatment with
5-FU and LY294002 resulted in a mixed pattern of the
morphological changes observed in the cells treated
with each drug individually. The apoptotic cell popula-
tions were also measured by flow cytometry to analyze
their cellular DNA contents after staining with propi-
dium iodide and annexin V (Figure 5B). After the com-
bination treatment, apoptotic cells increased to a greater
extent than in cells treated with 5-FU alone.
5) Knockdown of LMP2A enhances the antiproliferation
effect of 5-FU treatment
To assess whether the chemoresistance to 5-FU in SNU-
719 cells is attributable to LMP2A, we knocked down
LMP2A mRNA transcripts using LMP2A siRNA, and
compared the antiproliferative effects of 5-FU treatment
in a time-dependent manner. LMP2A siRNA caused over
90% of reduction in LMP2A mRNA expression compared
to scrambled siRNA (Figure 6A). Because the survival cell
population (%) still was over 50% despite of high concen-
tration of 5-FU (< 1 mM), the IC50 of 5-FU treatment for
24 h could not be calculated after transfected with the
scrambled siRNA, but the IC50 of 5-FU was 82.2 ± 2.5
μM in cells transfected with LMP2A siRNA. IC50 of the
5-FU treatment for 48 h for LMP2A-siRNA-transfected
SNU-719 cells (36.0 ± 2.7 μM) was two-fold lower than
that for cells transfected with scrambled siRNA (78.6 ±
11.6 μM). Similar results were observed following treat-
ment with 5-FU for 72 h (Figure 6B). When cells trans-
fected with LMP2A siRNA were treated singly with 5-FU
or with the combined drugs (5-FU followed by
LY294002), the expression of p-AKT was significantly
reduced than that in cells transfected with the scrambled
siRNA (Figure 6C).
Figure 4 Cell-cycle effects of 5-FU and LY294002. SNU-719 cells
were incubated with 5-FU (10 μM) or LY294002 (20 μM), in single
or combined treatments, for 72 h. (A) Cell-cycle distributions were
measured by flow cytometry. The results are expressed as the mean
percentages of cells in the different phases of the cell cycle in each
sample (sum to 100%) in three independent experiments. (B)
Western blot analysis of retinoblastoma 1 (RB1), cyclin D3, CDK2,
cyclin A, and CDK4 was performed using the corresponding
antibodies to confirm the phase-specific cell-cycle effects of 5-FU
and LY294002 alone or in combination, as shown in (A).
Representative immunoblots are shown from three independent
experiments. Actin on the same immunoblot was used as the
loading control.
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synergistic cytotoxicity via activation of the mitochondria-
dependent apoptotic pathway
We evaluated changes in the signaling proteins of the
mitochondria-dependent apoptotic pathway, which are
known to be constitutively expressed in EBV-infected
cancers, when 5-FU was combined with LY294002. Bcl-
2 is a protein of the anti-apoptotic family, and Bak1 and
Bax are proteins of the pro-apoptotic family. Single
treatment with LY294002 did not change the expression
of Bcl-2 or Bak1 proteins compared with that in the
control. However, the expression of Bcl-2 was reduced
and that of Bak1 was slightly increased in cells treated
singly with 5-FU. When the two drugs were combined
sequentially, the expression of Bcl-2 was completely
diminished and the expression of Bak1 was similar to
that after a single treatment with 5-FU. There was no
change in Bax expression after any treatment. When the
two drugs were applied separately to the cells, p-p53
was slightly increased relative to that in the control. Its
expression was more significantly increased after the
sequential combination treatment than after individual
treatment with either of the two drugs (Figure 7).
Discussion
EBV-positive gastric cancer cell lines have been identi-
fied by several investigators, by detecting EBV nuclear
antigens (EBNAs), latent membrane protein 1 (LMP1),
or BARF0 [2,20]. However, the frequency of LMP2A
expression is lower in patients with EBV-positive gastric
cancer and in EBV-positive gastric cancer cell lines than
in B-cell malignant lymphomas [21-23]. It is difficult to
treat EBV-positive gastric cancer successfully because
significant resistance to cytotoxic anti-cancer drugs,
Figure 5 Apoptotic cell death induced by 5-FU, LY294002, or their combination. (A) Morphological changes were induced in SNU-719 cells
by combined treatment with 5-FU and LY294002. Nuclear fragmentation and condensation were evident in the cells treated with the sequential
combination of 5-FU and LY294002. (B) Flow-cytometric analysis of apoptosis was performed. The untreated cells and cells treated with the
experimental drugs were stained with propidium iodide and annexin V. The values are the averages of three independent experiments (mean ±
SD).
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has been demonstrated in laboratory studies and clinical
trials [24,25]. Only the lytic form of EBV is affected
when infected cancer cells are treated with gancyclovir
(GCV), and antiviral drugs are ineffective in some gas-
tric cancer cells, such as SNU-719, because EBV lytic
genes are expressed at very low levels [19]. Recently,
various experimental treatments for EBV-positive gastric
cancers have been studied to improve their efficacy.
Representative approaches include the combination of
5-aza-2-deoxycytidine or histone deacetylase (HDAC)
inhibitors with cytotoxic anti-cancer drugs or with anti-
viral drugs such as GCV [26,27]. We consider that epi-
genetic modification by HDAC is not essential for
Figure 6 Cytotoxic effects of 5-FU and the expression of p-AKT by drug treatment in cells transfected with LMP2A siRNA.( A )L M P 2 A
siRNA-silenced SNU-719 cells were subjected to RT-PCR for LMP2A in a time-dependent manner. (B) The inhibitory effects on cellular
proliferation caused by 5-FU treatment were more pronounced in SNU-719 cells transfected with LMP2A siRNA than in cells transfected with the
scrambled siRNA. (C) The expression of p-AKT was reduced further by 5-FU in cells transfected with LMP2A siRNA compared with in cells
transfected with the scrambled siRNA (NC).
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because it does not directly affect cellular signal trans-
duction pathways.
If the MAPK signal pathway or the phosphatidylinosi-
tol-3-kinase (PI3K)/AKT signal pathway is dysregulated
in epithelial cells or B-cell lymphomas, EBV is likely to
be changed into the lytic form [19,20]. Therefore, we
hypothesized that such cellular signal transduction path-
ways play important roles in the transformation of EBV
into the lytic form, and that resistance to cytotoxic anti-
cancer drugs can be overcome if these pathways are
effectively inhibited. We also assumed that LMP2A has
a greater effect on cellular signal transduction pathways,
in terms of converting EBV into the lytic form, than do
other viral proteins. Our results confirmed that EBV-
positive gastric cancer cells are resistant to 5-FU and
that this resistance is reduced when the expression of
phosphorylated nuclear factor kappaB (p-NFB) and
phosphorylated AKT (p-AKT) is decreased by combin-
ing 5-FU with LY294002, a PI3K inhibitor (Figure 3).
Furthermore, apoptosis was enhanced not only when
the PI3K/AKT signal pathway is inhibited, but also
when p-p53 expression is increased and Bcl-2 expres-
sion is reduced (Figure 7).
Even at high concentrations of 5-FU, the number of
drug-resistant SNU-719 cells was 20-30% higher than
that for the AGS EBV-negative gastric cancer cells. In
contrast, LY294002 strongly affected both SNU-719 cells
and AGS cells, regardless of their EBV status. However,
when EBV-positive gastric cancer cells were treated with
enzastaurin, which inhibits both PI3K and protein kinase
C (PKC), no cytotoxic effects were observed (data not
shown). Lee et al. [28] reported that synergistic or addi-
tive effects were observed in diverse gastric cancer cell
lines when treated with enzastaurin alone or in
combination with cytotoxic anti-cancer agents; however,
significant resistance to enzastaurin treatment alone was
observed only in SNU-719 cells (IC50 > 250 μM).
Among the various reported mechanisms of resistance
to 5-FU, such as multi-drug resistant proteins (MRP,
MDR1) and DPD, we focused on cell signaling proteins
[29]. However, previous in vitro studies have reported
that several chemotherapeutic agents (e.g., 5-FU, pacli-
taxel, cisplatin, irinotecan, and doxorubicin) can activate
NF-B, which results in notable suppression of the
apoptotic potential [13]. AKT is an important regulator
of cell survival and apoptosis. Constitutive activation of
NF-B is observed in various malignant cells, which
implies that activated NF-B induced by AKT may play
a major role in the chemo-resistance of gastric cancer
cells [16-18,30,31]. The expression of this protein is
altered in various human tumors, and this aberrant
expression may contribute to cellular chemo-resistance.
It phosphorylates IB, thus promoting IB degradation
and thereby increasing the activity of the well-known
cell survival factor, NF-B.
We investigated how the expression of p-AKT and
p-NF-B changes with the induction of resistance to
5-FU, based on the finding that LMP2A activates the
PI3K/AKT signaling pathway [32]. When SNU-719 cells,
with the PI3K/AKT signaling pathway activated by
LMP2A, were treated with 5-FU, p-AKT expression was
increased. LY294002 showed a significant anti-prolifera-
tive effect in both SNU-719 and AGS cells, regardless of
their EBV status. In particular, it reduced p-AKT
expression remarkably in SNU-719 cells and produced
excellent cytotoxicity compared with treatment by 5-FU
alone (Figure 3). Generally, over-expression of p-NFB
protein is important for drug resistance to 5-FU, but the
activation of PI3K/AKT signal transduction induced by
LMP2A appears to be another important cause of resis-
tance to 5-FU in EBV-positive gastric cancer cells.
When SNU-719 cells expressing LMP2A were trans-
fected with LMP2A siRNA, the expression of p-AKT
was reduced and the anti-proliferative effect of 5-FU
was recovered. Despite the high concentration of 5-FU,
SNU-719 cells transfected with scrambled siRNA sur-
vived, but LMP2A-knockdown SNU-719 cells were sig-
n i f i c a n t l yr e d u c e d( F i g u r e6 ) .T h ec h a n g e si ng e n eo r
protein expression that facilitate the development of
gastric cancer have yet to be identified. However, dysre-
gulation of the PI3K/AKT signal pathway after EBV
infection is a possible mechanism in the carcinogenesis
of gastric cancer.
LY294002 was combined with 5-FU for different
sequential treatments and exposure times. When
LY294002 was followed by 5-FU, the expression of
p-AKT was increased and an antagonistic effect was
observed as a combination index [CI] value of 1.1 (data
Figure 7 Western blot analysis of Bcl-2 family members (Bak1,
Bcl-2, and Bax) and p-p53. The expression of Bak1, Bax, Bcl-2, and
b-actin proteins in SNU-719 cells was investigated. Sequential
treatment with 5-FU followed by LY2940002 significantly reduced
the expression of Bcl-2 protein but slightly increased the expression
of Bak1. However, there was no change in the expression of Bax
protein.
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Page 9 of 11not shown). However, the reverse sequential combina-
tion (i.e., 5-FU followed by LY294002) significantly
reduced p-AKT expression with a highly synergistic
effect (CI = 0.36). These results indicate that p-AKT
contributes to the resistance of EBV-positive gastric can-
cer cells to 5-FU.
The expression of p-NFB decreased in AGS EBV-
negative gastric cancer cells, depending on the concen-
t r a t i o no f5 - F Uw h e nu s e da l o n e .H o w e v e r ,i ti n c r e a s e d
when used in combination with LY294002. The CI value
obtained for the two drugs indicated additive effects. In
contrast, p-AKT expression increased after treatment
with 5-FU alone, but decreased when 5-FU was com-
bined with LY294002. In AGS EBV-negative gastric can-
cer cells, it is considered that apoptosis is induced by
inhibition of the NF-B signal pathway in the case of
treatment with 5-FU alone, and predominantly by the
inhibition of p-AKT expression and its downstream sig-
naling molecules in the case of treatment with
LY294002.
We observed that 5-FU increased the expression of
cyclin A, resulting in S-phase arrest of the SNU-719 cell
population. Compared with 5-FU alone, the combination
of 5-FU with LY294002 downregulated the expression of
cyclin D3 and CDK2, and upregulated the expression of
cyclin A and CDK4. Sequential treatment with 5-FU fol-
lowed by LY294002 resulted in a mixed pattern of DNA
condensation and large nucleated cells, when compared
with cells treated with the individual drugs. When SNU-
719 cells are treated with 5-FU or LY294002, alone or
in combination, it is postulated that apoptosis is induced
by the inhibition of DNA synthesis or G0/G1 arrest via
increased p-p53 expression and reduced p-NF-B
expression. It was also confirmed that apoptotic cells
were more significantly augmented by increased p-p53
and decreased Bcl-2 expression using combined treat-
ment than using 5-FU treatment alone. Leung et al. [10]
reported that most EBV-positive gastric cancer cells
express p53 protein at low to medium levels and that
another mechanism exists which induces the over-
expression of p53, in addition to the direct mutation of
p53 by EBV.
It is considered that the high levels of Bcl-2 expression
adopted as protection from apoptosis in EBV-positive
gastric cancer cells result in the natural death of fewer
cancer cells than in the case of EBV-negative gastric
cancer cells. In addition, increased Bcl-2 expression
results in chemo-resistance to anti-cancer drugs by inhi-
biting p53-mediated apoptosis [11,33]. However, some
studies have reported the absence of altered Bcl-2
expression or p53 accumulation in EBV-positive gastric
cancers [33]. Additional research is warranted regarding
the roles of Bcl-2 and p53 in the development of drug
resistance [34]. In EBV-positive SNU-719 cells,
LY294002 enhanced the sensitivity to 5-FU by downre-
gulating activated p-AKT and its downstream molecules,
and induced apoptosis by arresting the cell population at
G0/G1 phase. Furthermore, increased sensitivity to 5-FU,
with remarkable inhibition of the activated PI3K/AKT
signaling pathway, was observed in SNU-719 cells trans-
fected with LMP2A siRNA.
Conclusions
We demonstrated that the resistance to 5-FU in EBV-
positive gastric cancer cells, in which the PI3K/AKT
pathway had been activated, was caused by the induc-
tion of p-AKT expression as well as p-NF-Be x p r e s -
s i o n .W es u g g e s tt h a tt h ee f f e c t i v ei n h i b i t i o no f
activated p-AKT by sequential treatment with 5-FU and
LY294002 could overcome the 5-FU resistance through
increases in anti-proliferation, cell cycle arrest, and
induction of mitochondria-independent/-dependent
apoptotic pathways.
Progress has been made in overcoming cellular resis-
tance to cytotoxic anti-cancer drugs used for EBV-
positive gastric cancers. However, there are several lim-
itations to the treatment strategy of directly eradicating
EBV. Further studies are necessary to further improve
the therapeutic efficacy by adding antiviral drugs to the
combination of 5-FU and PI3K inhibitors, and to estab-
lish a standard treatment for patients with EBV-positive
gastric cancer.
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